Why Mayne Pharma shares have jumped ~85% and what is the $6.40 Gedeon Richter bid means for investors
(Image source: Canva)
Mayne Pharma shares increased approximately 85% following the Gedeon Richter's proposed $6.40 per-share acquisition which has valued the company around $604 million. This represents a significant premium and provides shareholders with an opportunity.
Mayne Pharma Group Limited (ASX: MYX) recently has announced about the acquisition deal on 17 November 2026 that has resulted in a rapid increase in the stock prices due to an agreement of a takeover with the Hungarian pharmaceutical firm Gedeon Richter Plc. In this acquisition, Gedeon Richter will buy 100% of Mayne Pharma at a price of $6.40 per share in cash. The current offer made is at a premium of 124%, 122% and 145% respectively to the company's 30-day, 90-day and 180-day volume-weighted average price.
Mayne Pharma's existing portfolio includes its estetrol-based combination pill alongside established and popular women's health and dermatology-based products. Its US commercial footprint and DistributeRx direct-to-patient platform also provide Richter with an established distribution network which would help in carrying operations efficiently and would also reduce the operating cost.
What does the deal mean for shareholders?
For shareholders, the biggest appeal is certainty and gain. Gedeon Richter is offering $6.40 in cash for every share, which values Mayne Pharma at about $604 million. That price is well above where the stock was trading before the news, sitting 124% over the 30-day average. Anyone who wants to cash out now gets a clear price rather than having to rely on the share price holding up.
This deal would offer an exit option to the existing shareholders at $6.40 per share and a higher premium in relation to the last traded price. This deal is not yet finalized and the shareholders have to look at the terms that come with this deal. This deal requires regulatory approvals along with the shareholder approval and then the final court approval. There is no financing condition.
What should investors now watch next?
Investors should now watch for the release of the scheme booklet, which will be providing further details on the transaction and the board's recommendation. Progress on the regulatory approvals and completion of the international business selling of to Evaris Pharma will also be important. Although the proposed $6.40 cash consideration offers a significant gains to previous trading levels and the transaction remains subject to several conditions and its completion is not guaranteed.
What could happen to Mayne Pharma shares before completion?
The company's share price may continue to remain closely linked to the proposed $6.40 acquisition price as the investors assess the likelihood and timing of the transaction happening. However, the difference right now between its market price and the cash price offer reflects the uncertainty going around until completion and the time required to obtain necessary approvals affect and any delays in regulatory clearances or shareholders rejection would be influencing market sentiment and share-price movements.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
TOP ASX STOCKS WORTH WATCHTING
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
ASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.